top
Search terms
Results 41 - 50 of 113 - ordered by :
Pages: 1 ... 2 3 4 5 6 7 8 ... 12
ESC365

Better adherence to lipid lowering guidelines in secondary prevention may result in substantial reduction in cardiovascular events

Date : 01/09/2019
ESC365

Prediction of cardiovascular events by atheromatous plaques detected by non-obstructive general angioscopy ; two-year results of EAST-NOGA Registry

Date : 01/09/2019
Escardio

The first reliable evidence of a link between major cardiovascular risk factors in children – serum cholesterol, blood pressure, body mass index (BMI), and smoking – with cardiovascular ...

Date : 01/09/2019
Escardio

Up to 50% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease. Prior randomised trials found declines in composite outcomes with non-culprit ...

Date : 01/09/2019
Escardio

Professor Bryan Williams (University College London, London, UK), ESC Task Force Chair for the 2018 ESC/European Society of Hypertension Guidelines2 and a presenter in the debate sets the scene: ...

Date : 01/09/2019
ESC365

Elevated plasma xanthine oxidoreductase activity predicts cardiovascular events in patients with heart failure with preserved ejection fraction

Date : 31/08/2019
Escardio

(1) “Nuts are a good source of unsaturated fat and contain little saturated fat,” said study author Dr Noushin Mohammadifard of Isfahan Cardiovascular Research Institute, Iran. ...

Date : 31/08/2019
Escardio

Rivaroxaban for stroke or TIA prevention in heart failure patients with sinus rhythm The results of the Commander HF trial about the effects of low dose Rivaroxaban in combination with antiplatelet ...

Date : 08/08/2019
Ehjcardiovascrec

The last three decades have seen significant advances in interventional and pharmacologic therapy for coronary artery disease (CAD). COX-1 is completely inhibited in over 99% of patients;1 however, ...

Cardiovascular Research, Friede, Kevin A, Voora, Deepak

Date : 01/08/2019 Item size : 137084 bytes
Escardio

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With ...

Date : 01/06/2019